Articles tagged with Liver Cancer
Researchers at Johns Hopkins Medicine have developed a new technology that uses 3D MRI scans to precisely measure living and dying tumor tissue, allowing for more accurate predictions of patient survival after chemotherapy. The technology has been shown to improve survival rates by up to 19 months in patients with liver tumors.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
Researchers identified a molecular link between liver cancer, cellular stress and health problems that increase the risk of developing this cancer. The protein CHOP promotes liver cancer in mice and may do so in humans too.
A study by University of Iowa researchers identifies CHOP as a protein that promotes liver cancer in mice, linked to cellular stress from obesity, alcoholism, and viral hepatitis. Elevated CHOP levels are found in human liver tumors, suggesting potential targets for therapies.
Michigan State University researchers discovered a genetic deficiency in male mice that triggers the development of liver cancer and type 2 diabetes. The study found altered NCOA5 gene levels led to glucose intolerance and hepatocellular carcinoma.
A team of Singapore scientists has made a breakthrough in understanding the molecular basis of bile duct cancer by mapping human genes disrupted in cholangiocarcinoma. The study identified several genes that were repeatedly disrupted in CCA development, suggesting new potential avenues for treatment.
Researchers at NUS found that activating Rho protein suppresses liver malignancies, providing evidence for signalling crosstalk between proteins in regulating liver overgrowth and cancer. The study paves the way for developing targeted therapeutics for liver cancer.
Researchers identified a novel HBV mutation in Korean men that may explain the gender disparity in liver cancer incidence. The mutation is associated with severe liver disease and was found exclusively in male patients.
Cancer is the leading cause of death among Hispanic Texans under 76, with lower rates of breast and colon cancer screenings. Despite advanced cancer stages at diagnosis, Hispanics experience higher survival rates than non-Hispanic whites.
Researchers developed a test that can clearly distinguish early liver cancer cells from normal liver cells by giving them a distinctive red-brown hue. The test uses a probe to detect and stain a microRNA called mir-21, which is found in liver cancer but not healthy liver cells.
A team of Singaporean and Taiwanese scientists have discovered that Aristolochic Acid (AA), a natural compound found in traditional Asian herbal remedies, is the most potent carcinogen identified to date, causing extensive DNA mutations. The study also reveals AA's possible link to liver cancer and calls for increased public awareness ...
A cohort study published in JNCI found a statistically significant elevated standardized incidence ratio for primary liver cancer among workers exposed to trichloroethylene. However, no significant risk was observed for kidney cancer or non-Hodgkin lymphoma. The authors suggest that further research is needed to confirm these findings.
Researchers found a key role for chaperones in protein assembly and regulation of the proteasome's functionality. The study may reveal new targets for anticancer drugs and advance research on Parkinson's and Huntington's diseases.
A randomized trial found that home-based health education increased HBV screening rates and knowledge about the disease among Hmong Americans, overcoming cultural and language barriers. The study suggests using lay health workers to improve access to screenings and diagnoses.
Research suggests that monitoring hepatic function with HIDA SPECT prior to and during radiation therapy can help tailor treatment plans for unresectable liver cancer patients. This assessment method allows for personalized radiation doses while minimizing the risk of liver injury.
Researchers at Johns Hopkins Medicine developed a method to track liver tumors' response to chemotherapy using paired CT scans, allowing for immediate feedback on treatment effectiveness. This technique has the potential to save patients from delayed diagnosis and reduced treatment efficacy.
Researchers at UNC discovered that the hepatitis C virus binds with microRNA miR-122 to protect itself, promoting viral replication. This interaction presents a promising target for new drugs to treat the infection.
A parasitic worm, prevalent in Southeast Asia, is believed to cause infections that contribute to liver cancer. The grant-funded research aims to understand how the worm's granulin secretion enhances tumorigenic environments and may lead to the development of a treatment.
A study found that enzyme levels in routine blood tests are a better predictor of liver cancer risk than hepatitis infection or other factors. The research used data from over 428,000 people and predicted 91% of liver cancer cases.
Researchers at the University of Southampton will investigate manipulating natural killer cells to attack hepatocellular cancer (HCC) cells. The study aims to create a method for clinical trials using NK cells for immunotherapy, with potential for improving treatment outcomes for HCC patients.
Researchers have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. Altering these proteins in mice impaired liver cancer development, providing new insights into liver cancer initiation.
A study published in Cancer Research identified a gene that disrupts the inflammatory process implicated in liver cancer. Laboratory mice bred without this gene lacked pro-inflammatory protein TREM-1 and protected themselves from developing liver cancer after exposure to carcinogens.
Researchers at Ohio State University found that liver cancer cells lose the ability to produce glucose due to microRNA-23a overexpression. Suppressing miR-23a might reverse this process and offer a new treatment for hepatocellular carcinoma, the most common form of liver cancer.
A new study published in the journal Stem Cell reveals an antibody developed by researchers can detect stem cells in organs like the liver and pancreas. This breakthrough helps understand tissue regeneration and cancer diagnosis and treatment.
A recent study published in the Journal of the National Cancer Institute found that high vitamin E intake from diet or supplements is associated with lower liver cancer risk. The analysis included 132,837 individuals and showed a clear inverse dose-response relation between vitamin E intake and liver cancer risk.
A large cohort study found that high vitamin E intake from diet or supplements is associated with a lower risk of liver cancer. The study included over 132,000 individuals and analyzed data from two population-based cohort studies conducted in China.
Researchers created a mouse model to study the role of AEG-1 in hepatocellular carcinoma, demonstrating its acceleration of disease progression and angiogenesis. The study paves the way for novel therapies targeting AEG-1.
Dr. Curtis Wray has been awarded a $729,000 grant to study disparities in liver cancer life expectancy among underserved populations. His research aims to identify factors contributing to the lower life expectancy of advanced liver cancer patients in these communities.
A recent study found that Alzheimer's patients who undergo hospitalization are at risk for complications such as delirium, loss of independence, and death. Researchers also highlighted the risks associated with Flavocoxid, a medical food used to treat osteoarthritis, which can cause liver injury in some patients. Additionally, screenin...
Scientists have made a significant breakthrough in understanding the cause of bile duct cancer by identifying several new genes frequently mutated in the disease. The research team discovered mutations in 187 genes using state-of-the-art DNA sequencing, shedding light on the molecular mechanisms of the disease.
A new biomarker has been identified to detect hepatitis B-infected patients at risk of developing liver cancer. Telomere length analysis revealed a significant association between longer telomeres and increased risk of liver cancer in patients with hepatitis B.
Researchers found that metformin reduces the level of glucose and inhibits fatty acid synthesis in mice, resulting in significantly fewer and smaller liver tumors. The drug has been linked to reduced risk of liver cancer in patients with Type II diabetes and obesity.
Wilmot researchers develop first genetically engineered mouse model for Intrahepatic Cholangiocarcinoma (IHCC), a type of bile duct cancer. The model incorporates common mutations in humans and enables testing of potential treatments, accelerating the discovery process.
Cancer tumors' metabolic profiles vary based on genes and tissue origin, necessitating individualized treatment approaches. The metabolome, in addition to the genome, is crucial for predicting metabolic changes and guiding therapy.
Researchers discovered a new commonality of chromosomal aberrations among embryonic cancers, including kidney, skeleton, and liver cancers. This finding could reveal the nature and progression of many different kinds of cancer by identifying patterns of mutation in the genome.
Mice genetically engineered to lack Foxa genes show reversed gender-related incidence of liver cancer, highlighting the protective role of estrogens against liver cancer. The study suggests that genetic markers called SNPs within Foxa binding sites may contribute to increased liver cancer risk in women.
The American Cancer Society's annual report shows a decline in cancer incidence and death rates, particularly among African American men and women. The report also highlights increasing trends in certain cancers, such as pancreatic and liver cancer, which may be linked to obesity and early detection practices.
A new study shows that targeting a specific microRNA, miR-221, can prolong the lives of mice with human liver cancer. The treatment also boosted activity of tumor-suppressor genes in these animals.
Recent Mayo Clinic studies identify risk factors for rising liver cancer cases, including hepatitis C infection and fatty liver disease. The studies suggest that screening for hepatitis C could improve treatment and survival rates for affected populations.
Dana-Farber Cancer Institute researchers have identified a mechanism that triggers inflammation in the liver and transforms normal cells into cancerous ones. They demonstrated that a particular micro-RNA, miR-124, can be harnessed to treat or prevent liver cancer.
Recent studies have uncovered significant limitations in liver cancer screening for patients with cirrhosis, emphasizing the need for enhanced diagnostic procedures. Most patients with cirrhosis prefer surveillance over non-screening, and ultrasonographic screening at different intervals did not improve detection of small liver cancers.
A study found that organ transplant recipients have a doubled cancer risk compared to the general population, with increased risks for various types of malignancies, including non-Hodgkin lymphoma and lung cancer. The increased risk is attributed to immunosuppression and oncogenic viral infections.
Two new studies advance the field of yttrium-90 radioembolization for liver cancer treatment. Researchers successfully modified blood vessels to maximize tumor-killing material delivery and simplify treatment. This technique allows for high local radiation doses with minimal risk to healthy tissues.
A new study reveals liver cancer incidence rates are rising in North America and Oceania, while declining in some Asian countries. Despite this, liver cancer remains a significant health issue in these regions, with high rates of infection and limited effective treatments.
Researchers tested a combination of oral drug sorafenib and microbead chemotherapy directly into tumors in advanced liver cancer patients. The treatment showed promise with no increased side effects compared to existing therapies.
Researchers at the University of Hawaii Cancer Center and The Queen's Medical Center will analyze gene expression and imaging data to detect liver cancer earlier. They aim to improve patient outcomes and reduce deaths from this deadly disease.
Researchers found that saffron significantly reduced the number and incidence of liver nodules, with complete inhibition observed at the highest dose. Saffron also inhibited the elevation of proteins indicating liver damage and blocked inflammation.
Inhibiting heat shock transcription factor 1 (HSF1) prevents liver cancer in mice by reducing access to glucose and lipids, which are critical for tumor growth. This finding supports the idea that altering metabolism can be an effective cancer treatment.
A new imaging technology reveals that metabolic shifts in cancer cells occur even before detectable tumors form, suggesting an early diagnostic tool for liver cancer. The study also shows that tumor metabolism changes precede tumor regression, offering potential strategies for cancer treatment and more effective therapies.
Leeds researchers investigate the effectiveness of pure Eicosapentaenoic Acid (EPA) in preventing the spread of bowel cancer to the liver. Previous studies have shown that EPA may prevent large bowel polyps, a precursor to colorectal cancer.
Researchers discover that celecoxib triggers liver cancer cell death by inhibiting a key protein, and combining it with chemotherapy drugs boosts effectiveness. The study suggests the possibility of a new treatment approach for liver cancer, which has a low five-year survival rate.
A recent study published in Gastroenterology highlights the increased risk of gastrointestinal complications in childhood cancer survivors after therapy. Risks for colostomy/ileostomy, cirrhosis or liver biopsy were highest among older patients and those exposed to abdominal radiation or certain chemotherapy treatments.
Boulton's research highlights include discovering key genes and enzymes involved in DNA repair mechanisms, including RTEL1 and ALC1. His work has led to novel therapeutic approaches for cancer treatment, particularly liver cancer.
The number of AIDS-defining cancers decreased, while non-AIDS-defining cancers increased significantly between 1991-2005. Lung cancer emerged as the most common malignancy in people with HIV but not AIDS.
A study found that diabetes is associated with a lower risk of prostate cancer in men, but a higher risk of other cancers and mortality in both men and women. Diabetes was linked to increased risks for colon, rectal, and liver cancers in men and women.
Researchers found that individuals with metabolic syndrome are at higher risk for developing liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The study, presented at the AACR 102nd Annual Meeting, highlights the importance of metabolic syndrome in increasing liver cancer incidence.
A four-year study confirms that Y-90 radioembolization is a safe and effective treatment for patients with metastatic liver cancer, particularly those who have failed chemotherapy. The procedure preserves patient quality of life and extends life, while also demonstrating anti-tumoral effects.
Researchers at VCU Massey Cancer Center have discovered a novel mechanism in gene regulation that contributes to the development of liver cancer. AEG-1 and SND1 proteins were found to increase RISC activity, leading to increased tumor growth. Inhibiting SND1 is proposed as a potential new avenue for treating liver cancer.
A long-term study found that consuming three or more drinks a day is associated with an increased risk of pancreatic cancer death in both men and women. Heavy drinking, specifically liquor consumption, also shows a significant association with pancreatic cancer mortality, particularly among never smokers.
A study at Cold Spring Harbor Laboratory has identified a therapeutic target for liver cancer using a monoclonal antibody that blocks the activity of the FGF19 gene. This approach shows promise in treating patients with FGF19 amplification, which can be used as a biomarker to predict treatment effectiveness.